Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2015-05-06 Earnings Release
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Earnings Release 2015
Earnings Release Classification · 100% confidence The document is titled "Company Announcement" and provides key financial highlights for a specific period (Q1 2015), specifically mentioning net sales figures (GBP 11.1 million) and expected royalty payments (DKK 22 million) related to a product (Arzerra). This structure—briefly summarizing period results and key financial outcomes without the depth of a full report (like a 10-K or IR)—is characteristic of an Earnings Release (ER). It is not a full transcript (CT), a formal annual report (10-K), or a comprehensive interim report (IR). Given its focus on initial results announcement, ER is the most appropriate classification. The document length (4972 chars) is substantial enough to be the release itself, not just a notice about a release (RPA). Q1 2015
2015-05-06 English
Earnings Release 2015
Earnings Release Classification · 98% confidence The document is titled "First Quarter 2015 Net Sales Figures for Arzerra® (Ofatumumab)" and provides specific financial metrics (net sales figures in GBP and expected royalty payments in DKK) for the first quarter (Q1 2015). This content aligns perfectly with an Earnings Release (ER), which is defined as the initial announcement of periodical financial results (key highlights only). It is not a comprehensive report (like 10-K or IR), nor is it a transcript (CT) or a presentation (IP). It is a concise announcement of period results. Q1 2015
2015-05-06 English
Earnings Release 2015
Earnings Release Classification · 99% confidence The document is titled "Company Announcement" and details the top-line results from a Phase III clinical study (COMPLEMENT 2) regarding the drug Arzerra for CLL. It announces positive results, mentions the primary endpoint was met, and states that data will be shared with regulatory authorities and at an upcoming medical conference. This structure—announcing key clinical trial results and future regulatory/conference plans—is characteristic of an Earnings Release (ER) or a general announcement related to financial/operational performance highlights, rather than a comprehensive report (10-K, IR) or a transcript (CT). Since it focuses on key operational/clinical achievements that drive financial performance, and it is an initial announcement of results, 'ER' (Earnings Release) is the most appropriate classification, even though it is not explicitly tied to a quarterly earnings period, as it serves the function of releasing material operational news to the market. Q2 2015
2015-04-27 English
Regulatory Filings 2015
Regulatory Filings Classification · 90% confidence The document is titled "Company Announcement" and details the positive top-line results from a Phase III clinical study (COMPLEMENT 2) for the drug Arzerra®. It provides key efficacy data (met primary endpoint of improved PFS), safety information, and context about the disease (CLL). This type of announcement, which releases preliminary or key financial/operational results for a period or event (in this case, clinical trial results), aligns best with an Earnings Release (ER) if it were financial results, or more generally, a significant operational update. Since it is a major operational/clinical milestone announcement, and not a full financial report (10-K, IR), a management discussion (MDA), or a transcript (CT), it functions as a primary announcement of results. Given the options, 'ER' (Earnings Release) is often used broadly for the initial release of significant performance indicators, even if non-financial. However, since this is a clinical trial result announcement, and not a standard quarterly financial earnings report, the most appropriate general category for a significant, non-standard operational announcement that isn't a formal regulatory filing like a 10-K or a specific report type (like AR or SR) is often the general Regulatory Filings (RNS) or, if we interpret 'Earnings Release' as 'Key Performance Indicator Release', ER. Given the context of a biotech company announcing clinical trial success, this is a critical operational update. It is not a proxy statement (DEF 14A), a management discussion (MDA), or a transcript (CT). It is a direct announcement of a major milestone. In many databases, major clinical trial updates are classified under general regulatory announcements or sometimes grouped with earnings releases as they drive investor sentiment. Since it is a direct announcement of results, and not an announcement *about* a report (RPA), I will classify it as a significant operational announcement. If 'ER' is strictly for financial earnings, 'RNS' is the best fallback. However, based on the structure (key highlights first, followed by details), it strongly resembles an Earnings Release format, even though the content is clinical. I will lean towards RNS as the most accurate catch-all for significant, non-standard operational announcements that aren't explicitly defined elsewhere, as it is a 'Company Announcement' detailing a major event.
2015-04-27 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is titled 'Company Announcement' and details a specific business event: Genmab receiving a milestone payment from Janssen due to progress in a Phase III clinical study for daratumumab. It discusses clinical trial progress, drug development, and financial guidance impact, but it is not a full financial report (10-K or IR), an earnings release (ER), or a formal proxy/governance document. This type of announcement, detailing operational or partnership progress that may have financial implications but is not a core financial statement, typically falls under general regulatory announcements or news releases. Since it is a formal announcement of a specific business event rather than a report itself, and it doesn't fit the specific categories like DIRS, DIV, or CAP, the most appropriate general category for a significant, non-standard business update is Regulatory Filings (RNS), which serves as a broad category for company news releases not covered elsewhere.
2015-04-16 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is titled "Company Announcement" and details a specific business event: Genmab receiving a USD 10 million milestone payment from Janssen due to progress in a Phase III clinical study for daratumumab. This is a specific, material business update that is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT). It relates to ongoing business operations and collaborations, which often fall under general regulatory announcements or investor relations updates. Since it is a specific announcement about a business event (milestone payment triggered by clinical progress) and not a change in management (MANG), financing (CAP), or dividend (DIV), the most appropriate general category for a specific, non-standard corporate update that isn't a core financial filing is Regulatory Filings (RNS), as it serves as a broad disclosure to the market. It is too detailed to be a simple Report Publication Announcement (RPA) and doesn't fit any other specific category like DIRS, LTR, or DIV.
2015-04-16 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.